Alchemee

Alchemee is a US-based manufacturer specializing in science-backed skincare solutions, delivering effective products and personalized support aimed at enhancing long-term skin health for consumers and professionals alike. Alchemee, founded in 1995 and headquartered in El Segundo, US, develops skincare solutions focused on long-term skin health. In February 2022, Taro Pharmaceutical Industries Ltd. acquired Alchemee for USD 99.

3 mn from several investors including Galderma and EQT. CEO Tony Matkovic leads the company following the acquisition, which enables Taro to enhance its dermatology portfolio, particularly in acne treatment with the Proactiv brand. Alchemee specializes in developing science-based skincare solutions designed to promote long-term skin health. The company offers a diverse portfolio of brands that deliver effective skincare products and systems, accompanied by ongoing care and personalized support.

These products target various skin concerns, such as aging, hydration, and acne, providing consumers with comprehensive solutions to enhance skin quality. Alchemee serves a broad customer base that includes both individual consumers and skincare professionals across multiple geographical markets, including North America and parts of Europe. The company aims to offer life-changing results through its innovative formulations and customer-centric approach, ensuring their products meet the evolving needs of the skincare industry. Alchemee generates revenue through a combination of direct-to-consumer sales and partnerships with retailers and skincare professionals.

The transaction structure includes the sale of individual products, along with subscription models for ongoing skincare regimens, allowing clients to maintain their skincare routines seamlessly. While specific pricing details for flagship products are not disclosed, the company's offerings are positioned within a range that reflects high-quality, science-backed skincare solutions. This multifaceted approach enables Alchemee to foster strong relationships with its clientele, contributing to a sustainable revenue model that emphasizes both product efficacy and customer satisfaction. Following the acquisition on February 22, 2022, Taro Pharmaceutical Industries Ltd.

plans to leverage Alchemee's expertise to expand its dermatology portfolio and strengthen its presence in the acne treatment market. The integration aims to enhance growth opportunities through synergies in research, development, and distribution. Plans for future growth include the development and launch of new products targeting specific skincare needs, with a clear focus on expanding into new geographical regions, particularly in Europe, by 2023.